Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2289
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaleemi, Saadat Ali-
dc.contributor.authorNoaman, Samer-
dc.contributor.authorBrookes, John-
dc.contributor.authorDick, Ronald-
dc.date.accessioned2024-04-09T04:24:17Z-
dc.date.available2024-04-09T04:24:17Z-
dc.date.issued2024-01-
dc.identifier.citationHeart Lung Circ . 2024 Jan;33(1):33-37.en_US
dc.identifier.issn1443-9506en_US
dc.identifier.urihttp://hdl.handle.net/11434/2289-
dc.description.abstractBackground: Severe aortic stenosis is the most common acquired valvular disorder. Balloon aortic valvuloplasty (BAV) is considered for patients who are not suitable for surgical aortic valve replacement (SAVR) and transcatheter aortic valve insertion (TAVI). The American Heart Association and European Society of Cardiology recommend BAV as a bridging procedure for SAVR and TAVI due to the significant morbidity and mortality associated with it. We aim to investigate the morbidity and mortality associated with BAV only, BAV bridged to TAVI and TAVI-only patients over 3 years in Epworth Richmond, a tertiary hospital in Victoria, Australia. Methods: We divided patients into three groups including BAV only, BAV bridged to TAVI and TAVI only and assessed the baseline demographics, procedural complications, and mortality between the groups. Results: Of 438 patients, 26 patients underwent BAV only, 36 patients bridged to TAVI post-BAV and 376 patients underwent TAVI directly. All patients had significant reductions in their mean AV pressure gradient (p<0.01). There was no significant difference in periprocedural morbidity and mortality between the groups. At 6-month follow-up, the mortality in patients undergoing only BAV was 31%, compared with 8.3% in BAV bridged to TAVI and 1.9% in TAVI-only group (p<0.01). The 12-month follow-up demonstrated a similar pattern; 42.3% vs 13.9% vs 4.5% (p<0.01). Conclusions: This study suggests no significant difference in inpatient and periprocedural morbidity and mortality between the three groups but a significant mortality benefit at 6-month and 12-month post valve insertion, either directly or post BAV.en_US
dc.publisherElsevieren_US
dc.subjectAortic stenosisen_US
dc.subjectBalloon aortic valvuloplastyen_US
dc.subjectSurgical aortic valve replacementen_US
dc.subjectTranscatheter Aortic Valve Insertionen_US
dc.subjectCardiac Sciences Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleClinical outcomes associated with balloon aortic valvuloplasty in the contemporary era.en_US
dc.typeJournal Articleen_US
dc.identifier.doidoi: 10.1016/j.hlc.2023.10.019.en_US
dc.identifier.journaltitleHeart, Lung & Circulationen_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/38142218/en_US
dc.description.affiliatesDepartment of General Medicine, Monash Health, Melbourne, VIC, Australiaen_US
dc.type.studyortrialComparative Studyen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cardiac Sciences

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.